VCBeat Health Contact Us
Home GSK Strikes Multiple Strategic Deals in a Single Day to Bolster Pipeline in Allergy, Oncology, and HIV

GSK Strikes Multiple Strategic Deals in a Single Day to Bolster Pipeline in Allergy, Oncology, and HIV

Jan 20, 2026 18:44 CST Updated 18:44
GSK

Pharmaceutical R&D Manufacturer

RAPT

Anti-cancer Biopharmaceuticals Manufacturer

Jiyu

Innovative Drug Developer

Image

Opportunities to go global are here!

Looking for PCSK9 small molecule inhibitor products, interested in global rights, current stage不限.

Interested companies are invited to contact immediately: PharmTimes BD Team
BD@drugtimes.cn

Image

Case Study on Impurity Identification and Structural Analysis in Drug Development | Porton·PharmaTimes Live


Main Body: 2500 Words
Estimated reading time: 7 minutes
At the 2026 JPM Conference, GSK R&D Director Tony Wood emphasized,GSKCurrently at the peak of R&D execution, leveraging long-acting formulation technology, AI-driven target patient matching, and strategic business expansion to comprehensively accelerate pipeline progress in respiratory, hepatitis B, HIV, and oncology fields, ensuring continuous commercial growth. Against this backdropGSK Actively Expands Its Layout, Reaching Multiple Collaboration Deals in a Single Day.
Image
$2.2 Billion Acquisition! Core Pipeline Comes from a Chinese Pharmaceutical Company
On January 20, 2026, GSK announced a $2.2 billion acquisitionRAPT Therapeutics。According to the agreement, GSK will acquire all outstanding shares of RAPT for $58 per share in cash.Total equity value of approximately $2.2 billion.After deducting the cash of the target company,GSKThe upfront investment amounts to USD 1.9 billion.Affected by this news,RAPT's share price surged over 9%, reaching $35.10 per share.
Image
Screenshot source: Xueqiu
RAPT Therapeutics, Inc. is an American pharmaceutical company established in 2015, dedicated to the developmentInnovative Therapies in the Field of Inflammation and Immune Diseases. The core assets of this acquisition include those currently inPhase IIb Clinical Development StageOzureprubart, the drug isA long-acting anti-immunoglobulin E (IgE) monoclonal antibody for preventive protection against food allergens.
Image
Screenshot source: RAPT official website
Ozureprubart Demonstrates Significant Advantage in Dosing FrequencyThe data from the Phase IIb trial (prestIgE) is expected to be released in 2027, and the Phase III trial will cover both high-risk adult and pediatric populations simultaneously.
It is worth mentioning that,Ozureprubart was not originally developed by RAPT but was licensed from Jiyu Pharmaceutical.In December 2024, RAPT acquired ozureprubart from Jiyu for a total transaction amount of $707.5 million.(Original project code: JYB1904)）Global rights outside Greater China, with an upfront payment of $35 million and subsequent milestones totaling $672.5 million.
Therefore, GSK's acquisition this time only obtained the global rights of ozureprubart outside Greater China. In the future, GSK will collaborate with Jiyu Pharmaceutical.Payments based on R&D milestones and sales royalties.
The tender offer launch time isWithin 10 working days after the signing of the agreement, it is expectedThe delivery will be completed in the first quarter of this year.
Image
$285 Million! Development of PD-1 Monoclonal AntibodySubcutaneous Formulation
On January 20, 2026, South Korean pharmaceutical company Alteogen announced a collaboration with GSK's subsidiaryTesaroSign an exclusive license agreement. According to the agreement, Tesaro will obtain the rights to use ALT-B4 worldwide.For the development and commercialization of anti-PD-1 monoclonal antibodiesDostarlimabSubcutaneous formulation.
Image
Screenshot source:Alteogen Official Website
ALT-B4 isAlteogen Based on HybrozyA novel hyaluronidase developed using me™ technology.This enzyme can temporarily hydrolyze hyaluronic acid in the extracellular matrix, thereby supporting high-volume subcutaneous administration as an alternative to the typically required intravenous infusion.
In return,AlteogenWill receive an upfront payment of $20 million and is eligible for up to$265 Million Milestone Payment with a Certain Percentage of Sales Royalty。Alteogen will be responsible for supplying Tesaro with ALT-B4 for clinical and commercial use.
Dostarlimab (brand name: Jemperli) was initially developed by AnaptysBio.In 2014, AnaptysBio licensed its development and commercialization rights toTesaro, after which GSK furthered its efforts through acquisitionsTesaroObtained the global exclusive license rights for dostarlimab.
Dostarlimab was approved for marketing in 2021 and has currently been approved in the United States for four indications, including "adult patients with recurrent or advanced endometrial cancer who have mismatch repair deficiency (dMMR) and whose disease has progressed during or after treatment with a platinum-containing regimen."In the first three quarters of 2025, the sales of dostarlimab were approximately$785.2 million, a year-on-year increase of93%。
Notably, in November 2025, Tesaro was still "in court" with AnaptysBio over the rights to dostarlimab.
Image
Pfizer Exits, GSK andShionogi Co-Chairs ViiV
January 20, 2026, GSK andShionogi & Co., Ltd.Jointly announced that they have reached an agreement with PfizerShionogi to Take Over Pfizer’s Stake in ViiV Following AgreementHealthcare 11.7% of the equity. After the transaction is completed, Shionogi's equity stake in ViiV will increase to 21.7%, while GSK will continue to maintain its controlling position with 78.3%.
Image
Screenshot source: GSK official website
Under the terms of the agreement, ViiV will issue new shares to Shionogi at a price of $2.125 billion, while canceling the shares held by Pfizer.Pfizer will receive $1.875 billion as an exit compensation, while GSK will receive a special dividend of $250 million (paid in pounds).
ViiV was initially established as a joint venture between GSK and Pfizer, with both companies transferring their HIV assets to the new entity. In 2012, Shionogi joined as the third shareholder.ViiV MainLayoutLong-actingHIVAntiviral research direction, with its core pipeline Cabenuva(Cabotegravir+Rilpivirine) injected once a month or every two months has been approved in many countries and regions around the world.
References:
1.https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-rapt-therapeutics/
2. Snowball
3.https://rapt.com/pipeline/
4.https://www.gsk.com/en-gb/media/press-releases/gsk-pfizer-and-shionogi-agree-on-changes-to-viiv-healthcare-shareholding/
5.https://alteogen.com/en/sub/ir/news.php?mode=view&bid=13&idx=205&page=1
6. Other Public Information

6. Cover Image/Abstract Image Source: Ji Meng AI
Image

Over 500 Million HKD! Insilico’s NLRP3 Inhibitor Licensed to Hengtai Bio for CNS Diseases

2026-01-20

Image

Wang Xiaodong: The 15 Years of NIBS

2026-01-19

Image

$630 Million! AstraZeneca and CIBOMAN Reach Another CAR-T Licensing Agreement

2026-01-19

Image

Copyright Statement/Disclaimer

This article is an original piece.

This article is for informational exchange purposes only and does not provide any commercial, medical, or investment advice.

The images, videos, fonts, music, and other materials in the article are either authorized genuine works purchased by PharmaTimes, sourced from the WeChat public image library, taken from the company's official website or the Internet, or used under the CC0 protocol. All copyrights belong to the respective owners, and PharmaTimes makes every effort to credit the sources.

If you have any questions, please contact us.

Sincerely grateful!

DrugTimes Official Website: www.drugtimes.cn

Contact Information:

Phone: 13651980212

WeChat: 27674131

Email: contact@drugtimes.cn

图片
ImageClickView more exciting content!